Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 12Completed 9Withdrawn 2Unknown 1Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Colorectal Neoplasms 16Glioblastoma 8Ovarian Neoplasms 7Colonic Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Breast Neoplasms 6Pancreatic Neoplasms 5Rectal Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Hepatocellular 4Uterine Cervical Neoplasms 3Neoplasm Metastasis 3Lung Neoplasms 3Neoplasms 2Melanoma 2Liver Neoplasms 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Central Nervous System Neoplasms 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrence 1Rectal Cancer Patients 1Prostatic Neoplasms 1Platinum-Refractory Fallopian Tube Carcinoma 1Peritoneal Neoplasms 1Optic Nerve Diseases 1

Interventions

pembrolizumab 3NVP-BKM120 2Bevacizumab 2trastuzumab duocarmazine 1talazoparib 1sitravatinib 1ponatinib 1niraparib 1mirvetuximab soravtansine 1lenvatinib 1dostarlimab 1dactolisib 1bemarituzumab 1Trastuzumab 1Taxes 1TAS-116 1Sevoflurane 1Radiotherapy 1Propofol 1Proflavine 1Polymerase Chain Reaction 1Paclitaxel 1PM 01183 1Methods 1Metformin 1Megestrol Acetate 1Magnetic Resonance Spectroscopy 1Letrozole 1Interviews as Topic 1Gene Expression Profiling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Endometrial Neoplasms × Bevacizumab × Clear all
NCT07146919 2026-04-23

ANGELICA

Centre Leon Berard

Phase 1/2 Withdrawn
Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT03836157 2019-06-27

Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer

University of Oklahoma

Phase 2 Withdrawn
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡